Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland

References

• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
   PubMed Web of Science ®Google Scholar
• Fredheim OM, Kaasa S, Fayers P, et al. Chronic non-malignant pain patients report as poor health-related quality of life as palliative cancer patients. Acta Anaesthesiol Scand 2008;52:143-8
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Singh V, Datta S, et al. Comprehensive review of epidemiology, scope, and impact of spinal pain. Pain Physician 2009;12:E35-70
   PubMed Web of Science ®Google Scholar
• van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-49
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO’s Pain Ladder. Accessed from http://www.who.int/cancer/palliative/painladder/en [8 November 2010]
   Google Scholar
• Zech DF, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995;63:65-76
   PubMed Web of Science ®Google Scholar
• The British Pain Society. Cancer pain management. Accessed from: http://www.britishpainsociety.org [10 November 2010]
   Google Scholar
• Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93
   PubMed Web of Science ®Google Scholar
• The British Pain Society. Opioids for persistent pain: good practice. Accessed from: http://www.britishpainsociety.org [10 November 2010]
   Google Scholar
• Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Ger Soc 2009;57:1331-46
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009;25:1517-28
   PubMed Web of Science ®Google Scholar
• Likar R, Kayser H, Sittl R, et al. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther 2006;28:943-52
   PubMed Web of Science ®Google Scholar
• Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13:219-30
   PubMed Web of Science ®Google Scholar
• Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:688-95
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2010;10:428-50
   PubMed Web of Science ®Google Scholar
• Grünenthal GmbH. Transtec 35, 52.5 and 70 micrograms transdermal patch – Summary of Product Characteristics. Accessed from: http://www.grunenthal.com/grt-web/115100044.jsp [10 November 2010]
   Google Scholar
• Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic 2003;15:193-202
   Web of Science ®Google Scholar
• Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003;25:150-68
   PubMed Web of Science ®Google Scholar
• Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26:1808-20
   PubMed Web of Science ®Google Scholar
• Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005;21:1147-56
   PubMed Web of Science ®Google Scholar
• Muriel C, Failde I, Micó JA, et al. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther 2005;27:451-62
   PubMed Web of Science ®Google Scholar
• Barutell C, Camba A, González-Escalada JR, et al. Efficacy and safety of buprenorphine TDS in conjunction with oral tramadol or morphine as rescue medication in the treatment of 390 patients with chronic pain: a summary of two retrospective Spanish multicentre studies. J Appl Ther Res 2007; 6:14-24
   Google Scholar
• Camba MA, Rodríguez-López MJ, Muriel C, Grupo de Studio de Opioides de la Socieda Española del Dolor. Buprenorphine TDS in the treatment of chronic nociceptive, neuropathic and cancer-related pain. J Appl Ther Res 2007;6:3-13
   Google Scholar
• Barutell C, Camba A, González-Escalada JR, et al. High dose transdermal buprenorphine for moderate to severe pain in Spanish pain centres—a retrospective multicenter safety and efficacy study. Pain Pract 2008;8:355-61
   PubMedGoogle Scholar
• Likar R, Vadlau EM, Breschan C, et al. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin J Pain 2008;24:536-43
   PubMed Web of Science ®Google Scholar
• Muriel Villoria C, Perez-Castejon Garotte JM, Sanchez Magro I, et al. Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study. Med Clin 2007;128:204-10
   PubMed Web of Science ®Google Scholar
• Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009;122:114-20
   PubMed Web of Science ®Google Scholar
• Rossiter A, Souney PF. Interaction between MAOIs and opioids: pharmacologic and clinical considerations. Hosp Formul 1993;28:692-8
   Google Scholar
• Haroutiunian S, Lecht S, Zur AA, et al. The challenge of pain management in patients with myasthenia gravis. J Pain Palliat Care Pharmacother 2009;23:242-60
   PubMedGoogle Scholar
• Varrassi G, Müller-Schwefe G, Pergolizzi J, et al. Pharmacological treatment of chronic pain – the need for CHANGE. Curr Med Res Opin 2010;26:1231-45
   PubMed Web of Science ®Google Scholar
• Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008;3:421-30
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313
   PubMedGoogle Scholar
• Sittl R, Nuijten M, Nautrup BP. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clin Ther 2006;28:1144-54
   PubMed Web of Science ®Google Scholar
• Schmitz S, Bruch HR, Hagen-Aukamp C. Transdermal buprenorphine in patients with cancer-related pain in oncological practice. J Appl Ther Res 2008;6:20-31
   Google Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
   PubMed Web of Science ®Google Scholar